ArticleNPJ primary care respiratory medicine2019
Presentation of lung cancer in primary care.
Article in NPJ primary care respiratory medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- [Cancer prevention recommendations: Update 2024].Atencion primaria · 2024Guideline
- Hidden systems in primary care cancer detection: an embedded qualitative intervention development study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2024Article
- Current Evidence for a Lung Cancer Screening Program.Portuguese journal of public health · 2024Review
- Anti-proliferative activity, molecular genetics, docking analysis, and computational calculations of uracil cellulosic aldehyde derivatives.Scientific reports · 2023Article
- Optimizing the implementation of lung cancer screening in Scotland: Focus group participant perspectives in the LUNGSCOT study.Health expectations : an international journal of public participation in health care and health policy · 2022Article
- [PAPPS Expert Groups. Cancer prevention recommendations: Update 2022].Atencion primaria · 2022Article
- Lung cancer and Covid-19: lessons learnt from the pandemic and where do we go from here?NPJ primary care respiratory medicine · 2022Article
- Is the combination of bilateral pulmonary nodules and mosaic attenuation on chest CT specific for DIPNECH?Orphanet journal of rare diseases · 2021Article
- Molecular biomarkers in early stage lung cancer.Translational lung cancer research · 2021Review
- LncRNA CBR3-AS1 potentiates Wnt/β-catenin signaling to regulate lung adenocarcinoma cells proliferation, migration and invasion.Cancer cell international · 2021Article
- Influence of respiratory function training under the mode of mutual-assisted patients on postoperative pulmonary infection and immune function on lung cancer.American journal of translational research · 2021Article
- Potential of modern circulating cell-free DNA diagnostic tools for detection of specific tumour cells in clinical practice.Biochemia medica · 2020Review
- SMAD-6, -7 and -9 are potential molecular biomarkers for the prognosis in human lung cancer.Oncology letters · 2020Article
- Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis.Disease markers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Survival from lung cancer has seen only modest improvements in recent decades. Poor outcomes are linked to late presentation, yet early diagnosis can be challenging as lung cancer symptoms are common and non-specific. In this paper, we examine how lung cancer presents in primary care and review roles for primary care in reducing the burden from this disease. Reducing rates of smoking remains, by far, the key strategy, but primary care practitioners (PCPs) should also be pro-active in raising awareness of symptoms, ensuring lung cancer risk data are collected accurately and encouraging reluctant patients to present. PCPs should engage in service re-design and identify more streamlined diagnostic pathways-and more readily incorporate decision support into their consulting, based on validated lung cancer risk models. Finally, PCPs should ensure they are central to recruitment in future lung cancer screening programmes-they are uniquely placed to ensure the right people are targeted for risk-based screening programmes. We are now in an era where treatments can make a real difference in early-stage lung tumours, and genuine progress is being made in this devastating illness-full engagement of primary care is vital in effecting these improvements in outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.